The two companies have entered into a collaboration to promote and democratise access to mRNA production technologies worldwide by launching Quantoom's Nfinity platform
Quantoom Biosciences has announced a new collaboration with Stevanato Group, a provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life science industries, with the goal of promoting and democratising access to cutting-edge mRNA production technologies worldwide.
The focus of this collaboration lies in harnessing the potential of Quantoom's revolutionary Nfinity Platform, a state-of-the-art, fully automated mRNA production platform, to contribute to the betterment of global health.
This collaboration brings together the innovative capabilities of both industry leaders with a shared vision to enhance global health outcomes through advanced engineering and scientific solutions.
The Nfinity Platform comprises multiple systems, designed with a small footprint, seamless automation, and cost-effectiveness.
Tailored to cater to the burgeoning demand for DNA and mRNA manufacturing and encapsulation, these systems are synergistically integrated with custom single-use consumables and ready-to-use reagent premixes. By combining their respective expertise, Quantoom and Stevanato Group will strive to cultivate a scalable optimised technology portfolio that would enable the economical production of mRNA on a global scale, thereby advancing the treatment landscape and improving global health.
Together, our companies can enable customers to introduce new mRNA-based drugs into the market faster, benefiting the patients waiting for them
- Andrea Zambon, Corporate Business Development Director at Stevanato Group
“Our journey began less than two years ago with a vision to revolutionise mRNA production, and today, I am immensely proud of the strides we've made. The collaborative efforts poured into our Nfinity Platform have yielded an exceptional automated mRNA production solution. The vitality of this collaboration with Stevanato Group underscores the innovative spirit that drives us,” said José Castillo, CEO at Quantoom Biosciences.
“Stevanato Group has the potential to bring innovation to the mRNA field,” said Andrea Zambon, Corporate Business Development Director at Stevanato Group. “Our expertise and capabilities in primary packaging, equipment, and analytical services for biopharmaceutical manufacturing make Stevanato Group the natural partner for Quantoom. Together, our companies can enable customers to introduce new mRNA-based drugs into the market faster, benefiting the patients waiting for them.”